Obesity is a well-established driver of insulin resistance and cardiorenal risk, and SGLT2 inhibitors exert multiple favorable metabolic effects—including weight loss, blood pressure reduction, and natriuresis—that may be especially beneficial in this population. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.